PAM50 gene signature is prognostic for breast cancer patients treated with adjuvant anthracycline and taxane based chemotherapy.
Saved in:
| Title: | PAM50 gene signature is prognostic for breast cancer patients treated with adjuvant anthracycline and taxane based chemotherapy. |
|---|---|
| Authors: | Liu, M. C., Pitcher, B. N., Mardis, E. R., Davies, S. R., Snider, J. E., Vickery, T., Reed, J. P., DeSchryver, K., Singh, B., Friedman, P. N., Gradishar, W. J., Perez, E. A., Martino, S., Citron, M. L., Norton, L., Winer, E. P., Hudis, C. A., Perou, C. M., Ellis, M. J., Barry, W. T. |
| Source: | Cancer Research. Dec2012 Meeting Abstracts, Vol. 72 Issue 24a, p585-586. 2p. |
| Database: | Academic Search Ultimate |
Be the first to leave a comment!
